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Chronic myelomonocytic leukemia (CMML) is a complex clonal hematological disorder classiﬁed among myelodysplastic (MDS)/
myeloproliferative neoplasms. Prognosis is poor and there is a lack of effective treatments. The hypomethylating agent decitabine
has shown activity against MDS and elderly acute myeloid leukemia, but there is little data focusing speciﬁcally on its efﬁcacy in
CMML. In this prospective, phase 2 Italian study, CMML patients received intravenous decitabine 20 mg/m2 per day on Days 1–5 of
a 28-day treatment cycle. Response was evaluated after four and six cycles; patients responding at the end of six cycles could
continue treatment with decitabine. Forty-three patients were enrolled; 450% were high-risk according to four CMML-speciﬁc
scoring systems. In the intent-to-treat population (n= 42), the overall response rate after six cycles was 47.6%, with seven complete
responses (16.6%), eight marrow responses (19%), one partial response (2.4%) and four hematological improvements (9.5%). After a
median follow-up of 51.5 months (range: 44.4–57.2), median overall survival was 17 months, with responders having a signiﬁcantly
longer survival than non-responders (P= 0.02). Grade 3/4 anemia, neutropenia and thrombocytopenia occurred in 28.6%, 50% and
38% of patients, respectively. Decitabine appears to be an effective and well-tolerated treatment for patients with high-risk CMML.
Leukemia (2018) 32, 413–418; doi:10.1038/leu.2017.186
INTRODUCTION
Chronic myelomonocytic leukemia (CMML) is a complex clonal
hematological disorder that is classiﬁed by the World Health
Organization among myelodysplastic (MDS)/myeloproliferative
neoplasms.1 The 2016 revision to the World Health Organization
classiﬁcation of tumors of the hematopoietic and lymphoid tissues
describes three categories of CMML based on blast count:2,3
CMML-0 (o2% peripheral blasts and o5% bone marrow blasts),
CMML-1 (2‒4% peripheral blasts and/or 5‒9% bone marrow
blasts) and CMML-2 (5‒19% peripheral blasts, 10‒19% bone
marrow blasts and/or presence of Auer rods). Before this revision,
patients with o2% peripheral blasts and o5% bone marrow
blasts were included in the CMML-1 category.4
Diagnosis can be difﬁcult, requiring a combination of morpho-
logic, histopathologic and cytogenetic approaches.5 The World
Health Organization diagnostic criteria for CMML are as follows:2,3
persistent monocytosis⩾ 1 × 109/l; no Philadelphia chromosome
or BCR-ABL1 fusion gene; exclusion of primary myeloﬁbrosis,
polycythemia vera and essential thrombocytothemia; no PDGFRA,
PDGFRB or FGFR1 rearrangements, or PCM1-JAK2 fusions if
eosinophilia present; o20% blasts in peripheral blood and bone
marrow; and dysplasia in one or more myeloid lineages.
If myelodysplasia is absent or minimal, a diagnosis of CMML can
still be made if a cytogenetic abnormality is present in the
hematopoietic stem cell, or if monocytosis has persisted for more
than 3 months with all other possible causes excluded.
Signiﬁcant heterogeneity makes prognosis in CMML difﬁcult to
estimate, but in general it is poor. Commonly used for MDS, the
original and revised International Prognostic Scoring Systems6,7
are not suitable for CMML, because they exclude patients with
proliferative disease. Newer prognostic models (such as the
CMML-speciﬁc prognostic scoring system,8,9 Groupe Francophone
de Myelodysplasies (GFM) model10 and the Mayo Molecular
Model11) take cytogenetics and somatic mutations into account.
Very recently, an integrated prognostic scoring system has been
proposed that takes clinical parameters, cytogenetics and somatic
mutations into account.12
The only potentially curative treatment option for CMML is
hematopoietic stem cell transplant, but this is not suitable for many
patients because of their age and comorbidities. There are currently
no prospective data on the beneﬁts and risks of hematopoietic stem
cell transplant in CMML. Management usually focuses on supportive
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care and cytoreductive therapy, depending on whether the disease
is dysplastic or myeloproliferative.13 Hydroxyurea is currently a
mainstay therapy for proliferative disease.14
The hypomethylating agents (HMAs) azacitidine and decitabine
have been shown to be active in MDS patients in randomized
phase 3 trials.15–17 However, the numbers of CMML patients in
these trials were limited and their results were not reported
separately. In two retrospective analyses of decitabine, overall
response rates (ORRs) ranged from 26 to 68% and 2-year survival
from 25 to 48%.18,19 In a prospective phase 2 study in which 39
CMML patients received 20 mg/m2 decitabine per day on days 1–5
of 28-day cycles, the ORR was 38% and 2-year survival was 48%.20
The European Medicines Agency has approved azacitidine for
the treatment of non-proliferative CMML (white blood cell (WBC)
count o12 000), but HMAs are not currently a licensed option for
treating proliferative forms. In Italy, several national societies
recommend that patients with myelodysplastic-type CMML and
⩾ 10% bone marrow blasts should be managed with supportive
therapy in combination with HMAs.13 Alongside the lack of
speciﬁc treatment options, CMML-speciﬁc response criteria were
not used in any clinical trials, having only been recently developed
by Savona et al.21
Here we report the results of a prospective phase 2 study that
assessed the efﬁcacy and safety of decitabine in Italian CMML
patients.
METHODS
Study design and patients
This was an open-label, phase 2 study carried out at 15 centres across Italy
between April 2010 and October 2011. Patients aged ⩾ 18 years with a
diagnosis of CMML according to World Health Organization criteria,4 an
Eastern Cooperative Oncology Group performance status ⩾ 2 and a life
expectancy ⩾ 6 months were eligible to enter the study. CMML patients
were classiﬁed according to FAB22 as dysplastic CMML (MDS-CMML) when
WBC counts ⩽ 13 000/mm3 or proliferative (myeloproliferative neoplasm-
CMML) when WBC 413 000/mm3. Patients with a WBC count ⩽ 12 000/
mm3 were required to have International Prognostic Scoring System
intermediate-2 risk. Those with a WBC count412 000/mm3 had to have at
least two of the following: blast cells45% in bone marrow, a cytogenetic
abnormality other than t(5;12) (q33;p13), anemia (that is, Hb o10 g/dl),
thrombocytopenia (that is, platelets o100 000/mm3), splenomegaly
(45 cm below the costal margin) and extramedullary localization. Patients
with a myeloproliferative or myelodysplastic syndrome other than CMML
and those who had acute blastic transformation of CMML with bone
marrow blast cells420% were excluded. Other exclusion criteria included
eligibility for allogenic stem cell transplant with an identiﬁed donor, CMML
with t(5;12) or PDGFBR rearrangement, intensive chemotherapy in the last
3 months and previous treatment with a HMA. Patients were eligible if
untreated or previously treated with hydroxyurea or etoposide given orally,
or non-intensive chemotherapy or intensive chemotherapy given more
than 3 months before inclusion. Patients received intravenous decitabine
(Dacogen; Janssen Pharmaceutica NV, Beerse, Belgium) 20 mg/m2 per day
on Days 1–5 of a 28-day treatment cycle. Discontinuation was allowed at
the patient’s request or if they experienced progression with blastic
transformation, grade 3/4 toxicity according to National Cancer Institute
criteria (except cytopenia) or other changes in their condition that the
investigator felt warranted removal of the patient from the study.
After a minimum of four treatment cycles, patients were assessed for
response to treatment. Responders were deﬁned as patients who achieved
hematological improvement or better according to International Working
Group 2006 criteria;23 these patients continued treatment for a further two
cycles. Minor responders and patients with stable disease were allowed to
continue in the study at the investigator’s discretion. Patients with
progressive disease were discontinued from the study. Patients who
completed all six treatment cycles were eligible to receive maintenance
treatment with decitabine. After completion of, or discontinuation from,
the study, patients were followed up every 4 months.
The study was carried out in accordance with the Declaration of Helsinki.
All patients provided written informed consent and all participating trial
sites gained approval from the relevant local ethics committee. This study
is registered on ClinicalTrials.gov (NCT01251627).
Objectives and outcome measures
The primary aim of the study was to assess the efﬁcacy of decitabine in the
treatment of CMML. The primary outcome measure was the ORR, deﬁned
as the proportion of patients achieving a complete response, marrow
complete response, partial response or hematological improvement.
Secondary outcome measures included overall survival (OS), event-free
survival, duration of response, the number of blood and platelet
transfusions, the number of days of hospitalization and safety.
Somatic mutations
Bone marrow samples were collected before treatment and DNA was
extracted from unsorted mononuclear cells. The methods used for
mutational sequencing have been published previously.24 Brieﬂy, target
regions (exons plus splice junctions) were captured and 500 ng of DNA
from each sample was quantiﬁed and sequenced using paired-end
sequencing. Sequences were aligned to the human genome and the
Genome Analysis Toolkit25 was used to perform further local indel
alignment and base-quality score recalibration, and to generate single-
nucleotide variation and indel calls. Variants with functional consequence
on genes were annotated and their presence identiﬁed in dbSNP 137, the
1000 Genomes Project, ESP6500 (the National Heart, Lung and Blood
Institute GO Exome Sequencing Project) and COSMIC 67.
Statistical analyses
Conventional treatments for CMML (hydroxyurea or etoposide) give ORRs
of no more than 15%. This study was designed to detect a clinically
relevant 20% increase in ORR with decitabine (that is, from 15 to 35%) with
85% power and a signiﬁcance level of 0.05. The planned sample size for
this single-stage Fleming-A’Hern phase 2 design was 39 patients.
Achievement of OR by ⩾ 11 patients after six cycles was to be considered
sufﬁcient to justify further investigation. To take into account losses to
follow-up for time-to-event endpoints, the sample size was increased by 10
and 43 patients were enrolled.
Primary efﬁcacy and safety data were analyzed for the intent-to-treat
population, that is, all patients who received at least one dose of
decitabine. Discrete variables were summarized by frequency and
percentage. Continuous variables were summarized by mean and s.d. or
median and interquartile range.
OS was deﬁned as the time from enrolment to death from any cause or
last follow-up evaluation. Event-free survival was deﬁned as the time from
enrolment to progression, transformation to acute myeloid leukemia or
death from any cause. Duration of response was deﬁned as the time from
clinical response to progression, transformation to acute myeloid leukemia
or death from any cause. These time-to-event endpoints were analyzed
using the Kaplan–Meier method.
Adverse events (AEs) were reported by type and grade according to the
Common Terminology Criteria for Adverse Events (version 3.0).
RESULTS
Patients
Between April 2010 and October 2011, 43 patients were enrolled
at 15 sites across Italy. The intent-to-treat population included 42
patients; their baseline characteristics are shown in Table 1. Most
patients were male (71.4%) and two-thirds had proliferative
CMML. Between 76 and 93% of patients were high- or
intermediate-risk (depending on the prognostic scoring system
applied retrospectively, as developed after inception of this study;
Table 1) and 15/42 had an ASXL1 mutation.
Figure 1 shows the ﬂow of patients through the study. The
median number of treatment cycles was 6 (range: 1–34). Twenty-
six patients (62%) received all six cycles; the most common
reasons for discontinuation were treatment failure (n= 9) and
death (n= 5).
Somatic mutations
The results of the analysis of the most frequent somatic mutation
found in CMML were not possible in all cases in this study and
have already been published previously in a study in which a
subset of the CMML patients treated with decitabine was analysed
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for methylation pattern, gene expression proﬁle and the presence
of somatic mutations.24 The incidence and type of mutation at
diagnosis is presented in Table 1. The most frequent mutations as
expected were those of SRSF2 (45.2%), TET2 (38.1%) and ASXL1
(35.7%).
There was no correlation between the presence of a single
mutation and pattern of response to decitabine.
Response rates
In the intent-to-treat population, the ORR was achieved in 20
patients (47.6%; lower 90% conﬁdence interval (CI): 34.2%)
(Table 2). Patients with CMML-1 had a higher ORR than those
with CMML-2 (53.8% vs 37.5%, P= 0.09). The ORR was also higher
in patients with dysplastic CMML than in those with proliferative
CMML (64.3% vs 39.3%, P= 0.12). Regarding reduction of
organomegaly, only 5/20 of responsive patients experienced a
decrease in spleen size.
Survival and progression
The median duration of follow-up was 51.5 months (range: 44.4–
57.2). Median OS was 17 months (Figure 2a). The 1-year, 2-year
and 3-year OS rates were 66.7% (95% CI: 50.3–78.7), 33.3% (95% CI:
19.8–47.5) and 28.6% (95% CI: 16.0–42.5), respectively. Patients
who responded to treatment at the end of treatment had a
signiﬁcantly longer OS than those who did not (log-rank = 0.02;
Figure 2b). Speciﬁcally, median OS (months) was signiﬁcantly
different (P= 0.0028): complete response: 31.08; marrow complete
response: 10.59; hematological improvement: 21.3; partial
response: not evaluable; stable disease: 2.36; progressive disease:
3.28. Median event-free survival was 8 months (Figure 3). The most
common event was death, which occurred in 36 patients (85.7%).
Thirty-two patients (76.2%) progressed and 24 (57.1%) had
transformation to acute myeloid leukemia. The 1-year, 2-year
and 3-year event-free survival rates were 35.7% (95% CI: 21.7–
49.9), 21.4% (95% CI: 10.6–34.7) and 19.1% (95% CI: 8.9–32.0),
respectively. The median duration of response after six cycles was
10 months (Figure 4). At 1-year, 52.6% (95% CI: 28.7–71.9) of
responders were still responding to treatment; the corresponding
ﬁgures at 2 and 3 years were 42.1% (95% CI: 20.4–62.5) and 26.3%
Table 1. Baseline characteristics (ITT population)
Patients, n 42
Median age, years (range) 71.5 (42–84)
Male/female, n (%) 30/12 (71.4/28.6)
CMML-1/CMML-2a, n (%) 26/16 (61.9/38.1)
dCMML/pCMML, n (%) 14/28 (33.3/66.7)
Hb g/dl, median (IQR) 9.8 (9.1–11.0)
AMC×109/l, median (IQR) 3.39 (2.23–7.25)
WBC× 109/l, median (IQR) 18.6 (13.9–28.1)
PLT× 109/l, median (IQR) 54.5 (34.0–75.0)
Bone marrow blasts %, median (IQR) 6.0 (3–12)
Cytogenetics, n (%)
Altered 12 (28.6)
Normal 28 (66.7)
Not evaluable 2 (4.7)
Splenomegaly, n (%) 22 (52.4)
Hepatomegaly, n (%) 19 (45.2)
Lymphadenomegaly, n (%) 6 (14.3)
Marrow ﬁbrosis, n (%) 13 (30.9)
ASXL1, n (%)
Mutated 15 (35.7)
Not evaluable 4 (9.5)
SRSF2, n (%)
Mutated 19 (45.2)
Not evaluable 5 (11.9)
TET2, n (%)
Mutated 16 (38.1)
Not evaluable 5 (11.9)
P53, n (%)
Mutated 3 (7.1)
Not evaluable 5 (11.9)
MMM prognostic risk categories, n (%)
High risk 13 (30.9)
Int-2 14 (33.3)
Int-1 10 (23.8)
Not evaluable 5 (12.0)
CPSS prognostic risk categories, n (%)
High risk 3 (7.1)
Int-2 20 (47.6)
Int-1 15 (35.7)
Low 2 (4.8)
Not evaluable 2 (4.8)
Mayo prognostic risk categories, n (%)
High risk 26 (61.9)
Int 13 (30.6)
Low 3 (7.1)
GFM prognostic risk categories, n (%)
High 14 (33.3)
Int 18 (42.9)
Low 10 (23.8)
Abbreviations: AMC, absolute monocyte count; CMML, chronic myelomo-
nocytic leukemia; dCMML, dysplastic CMML; CPSS, CMML-speciﬁc
prognostic scoring system; GFM, Groupe Francophone de Myelodysplasies;
Hb, hemoglobin; IQR, interquartile range; ITT, intent-to-treat; MMM, Mayo
Molecular Model; PLT, platelet; pCMML, proliferative CMML; WBC, white
blood cells; WHO, World Health Organization. Percentages may not total
100 owing to rounding. aDeﬁned according to the 2008 edition of the
WHO classiﬁcation of tumors of the hematopoietic and lymphoid tissues.
Figure 1. Patient disposition. Flow of patients from enrolment to
time of analysis.
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(95% CI: 9.6–46.8), respectively. In this group of patients, 15/42
carried ASXL1 mutations. OS for mutated patients was 17.6 months
vs 14.4 months for patients without ASXL1 mutation (P= 0.76).
There was a signiﬁcant difference in OS (Po0.001) according to
baseline methylation pattern: patients who had predictive
signature24 showed 23.03 months median OS vs 11.2 months
median OS of patients without predictive signature. Median OS
after decitabine treatment discontinuation was 3.28 months.
Two patients underwent hematopoietic stem cell transplant,
one ASXL1-mutated responder (transplanted at relapse) and one
ASXL1 unmutated, resistant to decitabine treatment. Their OS was
45.63 and 44.67 months, respectively. These patients were not
censored in the global OS evaluation.
Transfusions and hospitalizations
At baseline, 18 patients (42.9%) required transfusions. During the
treatment period, transfusions were carried out during 117/210
cycles; 39 patients needed at least one transfusion. Nine out of 18
patients became transfusion independent. During follow-up, 21
patients needed at least one transfusion. During the treatment
period, 9 patients had a total of 24 scheduled hospital admissions.
The median length of hospitalization was 6.5 (range 1.0–31.0)
days. Ten patients had a total 14 unscheduled hospital admissions:
4 caused by infective disease, 3 stroke, 3 trauma, 1 thrombocy-
topenia, 1 heart failure, 1 suspected pulmonary embolism and 1
disease progression. None of the hospitalizations was related to
the drug according to the treating physicians. During follow-up,
seven patients each had one unscheduled hospital admission.
Table 2. Overall clinical response (end of cycle 6 or at early
withdrawal)
Number (%) of patients
ITT (n= 42) CMML-1a
(n= 26)
CMML-2a
(n= 16)
dCMML
(n=14)
pCMML
(n=28)
ORR 20 (47.6) 15 (57.6) 5 (31.25) 9 (64.3) 11 (39.3)
CR 7 (16.6) 5 (19.2) 2 (12.5) 3 (21.4) 4 (14.3)
mCR 8 (19.0) 6 (23.1) 2 (12.5) 4 (28.6) 4 (14.3)
PR 1 (2.4) 0 (0.0) 1 (6.2) 0 (0.0) 1 (3.5)
HI 4 (9.5) 4 (15.3) 0 (0.0) 2 (14.2) 2 (7.2)
SD 9 (21.4) 4 (15.3) 5 (31.3) 0 (0.0) 9 (32.1)
PD 13 (31.0) 7 (26.9) 6 (37.5) 5 (35.7) 8 (28.6)
Abbreviations: CR, complete response; CMML, CMML, chronic myelomo-
nocytic leukemia; dCMML, dysplastic CMML; HI, hematological improve-
ment; ITT, intent-to-treat; ORR, overall response rate; mCR, marrow CR;
pCMML, proliferative CMML; PD, progressive disease; PR, partial remission;
SD, stable disease; WHO, World Health Organization. Percentages may not
total 100 owing to rounding. aDeﬁned according to the 2008 edition of the
WHO classiﬁcation of tumors of the hematopoietic and lymphoid tissue.
Figure 2. Overall survival. Kaplan–Meier curves showing OS in
(a) the intent-to-treat (ITT) population and (b) responders vs non-
responders. Vertical lines denote censored patients.
Figure 3. Event-free survival. Kaplan–Meier curves showing event-
free survival in the intent-to-treat (ITT) population. Vertical lines
denote censored patients.
Figure 4. Duration of response. Kaplan–Meier curves showing
duration of response. Vertical lines denote censored patients.
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Safety
The most common AEs during treatment were hematological:
thrombocytopenia, anemia and neutropenia (Table 3). In 50% of
cases, anemia was grade 3 or 4. More than three-quarters of
thrombocytopenia cases and over 80% of neutropenia cases were
grade 3 or 4. The most common non-hematological AEs were
gastrointestinal; all of these were grade 1 or 2. Two patients had
grade 5 AEs: one cardiac event and one bleeding event. Thirty-six
patients died: 5 during the 6-month study period and 31 during
follow-up. In 29 of these patients, MDS was the cause of death.
DISCUSSION
CMML is a disease that is difﬁcult to diagnose and has a poor
prognosis. There are currently no effective treatments for patients
who are unsuitable for hematopoietic stem cell transplant.
Dysplastic and proliferative forms of CMML are likely to require
different treatment approaches. Current recommendations are to
treat dysplastic CMML with supportive care plus azacitidine and
proliferative CMML with cytoreductive therapy to control prolif-
eration and reduce organomegaly.13
In our study, decitabine induced a response in approximately
half of patients, with responders having a survival advantage over
non-responders. Although patients with CMML-2 and those with
proliferative disease had lower response rates than those with
CMML-1 or dysplastic disease, the results in these subgroups were
encouraging. Decitabine was well tolerated in our elderly cohort;
the incidence and type of AEs were as expected.
The ORR in our study is slightly higher than that of 38%
reported in a previous study in 39 CMML patients conducted by
the GFM.20 Whereas we found CMML-1 patients to be more likely
to respond to treatment, the GFM CMML study showed the
opposite, with 50% of CMML-2 patients responding, compared
with 17.6% of CMML-1 patients. Median OS was similar in our
study and the GFM CMML study, but 2-year OS was lower in our
study (33.3% vs 48%).
Previous studies in mixed cohorts of patients with MDS and
related malignancies have linked increased response to HMAs to
mutations in TET226,27 (particularly when ASXL1 is not mutated27)
and DNTM3A.26 However, in a cohort of 40 patients from the
present study, we found that no somatic mutation, including
ASXL1, was predictive of response to decitabine in CMML.24
Likewise, the GFM CMML study also found no association between
response to decitabine and mutational status.20 This may indicate
a difference in the impact of mutational status between patients
with CMML and those with other myeloid malignancies. In
addition, the studies showing an association between somatic
mutations and response included patients who received azaciti-
dine, as well as patients who received decitabine.26,27
Although somatic mutations did not differentiate responders
from non-responders in our cohort, we found a pattern of 167
differentially methylated regions of DNA that was predictive of
response.24 Using this, we developed an epigenetic classiﬁer that
can accurately predict response to decitabine at the time of
diagnosis. It can take several cycles of treatment before it
becomes apparent whether the patient will respond or not; this
classiﬁer would allow potential non-responders to be identiﬁed
early and put onto an alternative treatment, rather than having to
endure months of fruitless treatment with decitabine.
Many of the patients in our cohort were high-risk according to
the prognostic scoring systems used; thus, we could not
determine whether high- and low-risk patients have a
differential sensitivity to decitabine. The median OS was
17 months, which compares favorably with best supportive care
and hydroxyurea.9,10 Such et al. used a cohort of patients receiving
best supportive care when developing the CMML-speciﬁc prog-
nostic scoring system.9 Patients who fell into the high-risk
category had a median OS of 5–9 months.9 Patients classed as
high-risk according to the GFM prognostic scoring system had a
median OS of 14.4 months.10 Most patients in this latter study
were receiving best supportive care, but hydroxyurea and HMAs
were also used. High-risk patients according to the Mayo
Molecular Model had a median OS of 16 months; the authors
do not report what treatment(s) the patients were receiving.11
Evaluation on whether the stratiﬁcation in single categories of risk
according to the speciﬁc models resulted in difference in response
was not possible because of the small numbers. According to
CMML-speciﬁc prognostic scoring system and GFM scores, the
differences in survival among groups was maintained after
decitabine, whereas according to Mayo scores there were no
differences in OS after treatment.
Decitabine appears to be an effective treatment for patients
with high-risk CMML, including those with proliferative disease.
Further research is needed to determine whether there is a
difference in response between low- and high-risk patients. Owing
to the rarity of CMML, large, speciﬁc trials can be difﬁcult to
conduct. However, we are currently conducting (within the
guidance of the European MDS Studies Coordination Ofﬁce) an
international, randomized, phase 3 trial comparing decitabine
(± hydroxyurea) with hydroxyurea in patients with advanced
proliferative CMML (ClinicalTrials.gov identiﬁer: NCT 02214407).
The results of this trial will provide further important insights into
the efﬁcacy of decitabine as a treatment for CMML, particularly in
patients with proliferative disease, for whom treatment with HMAs
is currently not a licensed option.
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